Selenium Donor Inhibited Hepatitis B Virus Associated Hepatotoxicity via the Apoptosis and Ferroptosis Pathways

Table 1

Demographics and clinical features of the HBV⁺-HCC patients, CHB patients and the healthy controls.

Clinical characteristics	HC group (n = 45)	CHB group (n = 45)	P1^a value	HBV^+-HCC group (n = 45)	P2^b value	P3^c value
Gender
Male	30	33	0.490	36	0.153	0.455
Female	15	12		9
Age
>55	21	23	0.673	20	0.832	0.527
≤55	24	22		25
HBV-DNA positive
Yes	–	36		34		0.612
>10^3 copies/mL
No	–	9		11
Anti-HBV treatment
Yes	–	24		26		0.6714
No	–	21		19
Tumor size
>5	–	–	–	20	–	0.670
≤5	–	–		25
Stage
I/II	–	–	–	23	–	0.834
III/IV	–	–		22
Lymphatic metastasis
Yes	–	–	–	19	–	0.516
No	–	–		26

^aP₁ was calculated by comparing the difference between CHB patients with the HCs group; ^bP₂ was calculated by comparing the difference between HBV⁺-HCC patients with the HCs group; ^cP₃ was calculated by comparing the difference between HBV⁺-HCC patients with CHB group.